97 Quick summary: Groundbreaking oncology research published in Genes and Diseases has revealed that targeting a specific mitochondrial protein known as UCP2 can halt the progression of aggressive acute myeloid leukaemia by triggering lethal oxidative stress in malignant blood cells. Laboratory and animal models demonstrate that silencing this protein disrupts mitochondrial function and causes an accumulation of branched chain amino acids, a metabolic vulnerability that can be dramatically amplified through targeted dietary supplementation to reduce cancer engraftment. These clinical findings carry profound significance for healthcare practice and public policy, offering a novel therapeutic blueprint that could guide next generation combination therapies towards overcoming treatment resistance and improving survival rates for leukaemia patients. Scientists have discovered a potential new way to treat Acute Myeloid Leukaemia by targeting its metabolic vulnerabilities. A study published in Genes and Diseases has identified a novel method to halt the progression of acute myeloid leukaemia, a blood cancer known for its aggressive nature and high relapse rates. Conducted by an interdisciplinary team from Shanghai Jiao Tong University School of Medicine, Fudan University, and Xinjiang Medical University, the research reveals that targeting a specific mitochondrial protein can trigger lethal oxidative stress in cancer cells, especially when combined with a dietary supplement. Acute Myeloid Leukaemia is characterised by frequent genetic mutations, mitochondrial dysregulation, and a high rate of therapeutic resistance. While standard chemotherapy is initially effective, many patients experience relapse. The study focused on mitochondrial uncoupling protein 2, known as UCP2. Though UCP2 is known to promote tumour cell growth and metastasis in various solid cancers, its role in hematological malignancies has remained unclear. Through bioinformatics analyses and primary clinical cohort data, the researchers found that UCP2 is significantly overexpressed in acute myeloid leukaemia patients, with elevated levels closely correlating with poor survival outcomes and therapeutic resistance. Laboratory experiments revealed that genetically silencing UCP2 impairs leukaemic cell proliferation and triggers apoptosis, or programmed cell death, while also disrupting mitochondrial function by increasing mitochondrial mass and reactive oxygen species (ROS), causing severe cellular damage. RNA sequencing and metabolic mass spectrometry analyses further showed that suppressing UCP2 causes a substantial intracellular accumulation of branched-chain amino acids, specifically leucine, isoleucine, and valine, which strongly induces oxidative stress and activates the PI3K/AKT/mTOR signalling pathway, halting leukaemogenesis. To validate this metabolic dependency, the researchers removed these amino acids from the cellular environment. This restored leukaemic cell survival and counteracted the anti-tumour effects of UCP2 inhibition. The team tested these findings in vivo using mouse xenograft models bearing human Acute Myeloid Leukaemia cells. Pharmacological inhibition of UCP2 using a selective inhibitor called genipin significantly reduced leukaemic blasts and improved overall survival. Dietary supplementation of branched-chain amino acids dramatically amplified genipin’s anti-tumour efficacy, leading to increased oxidative stress and sharply reduced leukaemia engraftment in both the bone marrow and peripheral blood. The authors note that additional studies are necessary before these targeted interventions can be translated into clinical therapies. Nevertheless, they conclude that targeting the UCP2/branched-chain amino acid/PI3K/AKT/mTOR signalling axis positions specific UCP2 inhibitors, potentially combined with targeted amino acid modulation, as compelling candidates for next-generation acute myeloid leukaemia treatments.